Literature DB >> 2221854

In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.

C Piketty1, F Derouin, B Rouveix, J J Pocidalo.   

Abstract

The in vivo effects of antimicrobial agents against Toxoplasma gondii were evaluated in mice that were infected intraperitoneally with 10(4) tachyzoites of the RH strain by determination of survival rates and study of the kinetics of growth of T. gondii in infected mice. At various intervals after infection, subcultures of serial dilutions of blood, lung, and brain homogenates were performed in fibroblast tissue cultures for determination of parasitic loads. Pyrimethamine (18.5 mg/kg per day), sulfadiazine (375 mg/kg per day), and clindamycin (300 mg/kg per day) were administered for 10 days from day 1 or day 4 after infection. Untreated control mice died within 9 days and showed early and predominant lung involvement. All mice treated with sulfadiazine administered from day 1 survived and were apparently healthy; parasitic loads decreased early after treatment, but a relapse was observed 5 days after the cessation of therapy. When pyrimethamine was administered from day 1, 7 of 11 mice died within 25 days; by determination of parasitic loads, the effect of pyrimethamine was only demonstrable from day 6, and a relapse was constantly observed after the cessation of therapy. When pyrimethamine and sulfadiazine were administered in combination, 100% of mice survived; when therapy was started at day 1, parasites remained undetectable; in mice treated from day 4, parasites were eradicated by day 8 but infection relapsed 8 days after the cessation of therapy. All mice treated with clindamycin from day 1 or day 4 died within 10 days, but parasitemia was always undetectable. These results indicate that study of the kinetics of parasitic loads in blood and organs may provide additional information on the effect of antimicrobial agents against T. gondii in regard to the evolution of the infection and may represent a reliable basis for the determination of therapeutic regimens in humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2221854      PMCID: PMC171854          DOI: 10.1128/AAC.34.8.1467

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Host, strain and treatment variation as factors in the pathogenesis of toxoplasmosis.

Authors:  J K FRENKEL
Journal:  Am J Trop Med Hyg       Date:  1953-05       Impact factor: 2.345

2.  The present status of the chemotherapy of toxoplasmosis.

Authors:  D E EYLES
Journal:  Am J Trop Med Hyg       Date:  1953-05       Impact factor: 2.345

3.  The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice.

Authors:  P R McMaster; K G Powers; J F Finerty; M N Lunde
Journal:  Am J Trop Med Hyg       Date:  1973-01       Impact factor: 2.345

4.  Comparative toxicological, chemotherapeutic and pharmacokinetic studies with sulphormethoxine and other sulphonamides in animals and man.

Authors:  E Böhni; B Fust; J Rieder; K Schaerer; L Havas
Journal:  Chemotherapy       Date:  1969       Impact factor: 2.544

5.  Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice.

Authors:  Y Suzuki; F K Conley; J S Remington
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

6.  Effect of clindamycin on acute and chronic toxoplasmosis in mice.

Authors:  F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

7.  In vitro effects of folate inhibitors on Toxoplasma gondii.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Comparative study of tissue culture and mouse inoculation methods for demonstration of Toxoplasma gondii.

Authors:  F Derouin; M C Mazeron; Y J Garin
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

9.  Pyrimethamine pharmacokinetics and its tissue localization in mice: effect of dose size.

Authors:  M D Coleman; G W Mihaly; G Edwards; S A Ward; R E Howells; A M Breckenridge
Journal:  J Pharm Pharmacol       Date:  1985-03       Impact factor: 3.765

10.  Clindamycin in a murine model of toxoplasmic encephalitis.

Authors:  J M Hofflin; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

View more
  18 in total

1.  Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors:  M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.

Authors:  M Brun-Pascaud; P Rajagopalan-Levasseur; F Chau; G Bertrand; L Garry; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.

Authors:  S Romand; C Della Bruna; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.

Authors:  M Brun-Pascaud; F Chau; L Garry; D Jacobus; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 5.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

6.  Innate refractoriness of the Lewis rat to toxoplasmosis is a dominant trait that is intrinsic to bone marrow-derived cells.

Authors:  Véronique Sergent; Bastien Cautain; Jamal Khalife; Didier Deslée; Patrick Bastien; Anne Dao; Jean-François Dubremetz; Gilbert J Fournié; Abdelhadi Saoudi; Marie-France Cesbron-Delauw
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy.

Authors:  Bakela Nare; John J Allocco; Paul A Liberator; Robert G K Donald
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.

Authors:  E Schoondermark-van de Ven; J Galama; T Vree; W Camps; I Baars; T Eskes; J Meuwissen; W Melchers
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.

Authors:  F Derouin; R Almadany; F Chau; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.

Authors:  S Romand; M Pudney; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.